144 related articles for article (PubMed ID: 11894393)
1. Anti-CD20 treatments and the lymphocyte membrane: pathology for therapy.
Borisch B; Semac I; Soltermann A; Palomba C; Hoessli DC
Verh Dtsch Ges Pathol; 2001; 85():161-6. PubMed ID: 11894393
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells.
Semac I; Palomba C; Kulangara K; Klages N; van Echten-Deckert G; Borisch B; Hoessli DC
Cancer Res; 2003 Jan; 63(2):534-40. PubMed ID: 12543813
[TBL] [Abstract][Full Text] [Related]
3. Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis.
Janas E; Priest R; Wilde JI; White JH; Malhotra R
Clin Exp Immunol; 2005 Mar; 139(3):439-46. PubMed ID: 15730389
[TBL] [Abstract][Full Text] [Related]
4. Empowering targeted therapy: lessons from rituximab.
Olszewski AJ; Grossbard ML
Sci STKE; 2004 Jul; 2004(241):pe30. PubMed ID: 15252219
[TBL] [Abstract][Full Text] [Related]
5. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels.
Czuczman MS; Olejniczak S; Gowda A; Kotowski A; Binder A; Kaur H; Knight J; Starostik P; Deans J; Hernandez-Ilizaliturri FJ
Clin Cancer Res; 2008 Mar; 14(5):1561-70. PubMed ID: 18316581
[TBL] [Abstract][Full Text] [Related]
6. Isolation and characterization of the B-cell marker CD20.
Ernst JA; Li H; Kim HS; Nakamura GR; Yansura DG; Vandlen RL
Biochemistry; 2005 Nov; 44(46):15150-8. PubMed ID: 16285718
[TBL] [Abstract][Full Text] [Related]
7. Cholesterol depletion inhibits src family kinase-dependent calcium mobilization and apoptosis induced by rituximab crosslinking.
Unruh TL; Li H; Mutch CM; Shariat N; Grigoriou L; Sanyal R; Brown CB; Deans JP
Immunology; 2005 Oct; 116(2):223-32. PubMed ID: 16162271
[TBL] [Abstract][Full Text] [Related]
8. BM-ca is a newly defined type I/II anti-CD20 monoclonal antibody with unique biological properties.
Nishida M; Uematsu N; Kobayashi H; Matsunaga Y; Ishida S; Takata M; Niwa O; Padlan EA; Newman R
Int J Oncol; 2011 Feb; 38(2):335-44. PubMed ID: 21152859
[TBL] [Abstract][Full Text] [Related]
9. CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts.
Chan HT; Hughes D; French RR; Tutt AL; Walshe CA; Teeling JL; Glennie MJ; Cragg MS
Cancer Res; 2003 Sep; 63(17):5480-9. PubMed ID: 14500384
[TBL] [Abstract][Full Text] [Related]
10. The autophilic anti-CD20 antibody DXL625 displays enhanced potency due to lipid raft-dependent induction of apoptosis.
Bingaman MG; Basu GD; Golding TC; Chong SK; Lassen AJ; Kindt TJ; Lipinski CA
Anticancer Drugs; 2010 Jun; 21(5):532-42. PubMed ID: 20216307
[TBL] [Abstract][Full Text] [Related]
11. [Rituximab resistance in B-cell lymphoma and its elimination].
Hatake K; Terui Y
Gan To Kagaku Ryoho; 2009 Apr; 36(4):548-51. PubMed ID: 19381025
[TBL] [Abstract][Full Text] [Related]
12. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
[TBL] [Abstract][Full Text] [Related]
13. CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells.
Hayden-Ledbetter MS; Cerveny CG; Espling E; Brady WA; Grosmaire LS; Tan P; Bader R; Slater S; Nilsson CA; Barone DS; Simon A; Bradley C; Thompson PA; Wahl AF; Ledbetter JA
Clin Cancer Res; 2009 Apr; 15(8):2739-46. PubMed ID: 19351771
[TBL] [Abstract][Full Text] [Related]
14. The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy.
Rawal YB; Nuovo GJ; Frambach GE; Porcu P; Baiocchi RA; Magro CM
J Cutan Pathol; 2005 Oct; 32(9):616-21. PubMed ID: 16176299
[TBL] [Abstract][Full Text] [Related]
15. [Rituximab, a chimeric anti-CD20 monoclonal antibody, in the treatment of B-cell lymphoma].
Tobinai K
Gan To Kagaku Ryoho; 2002 Mar; 29(3):473-80. PubMed ID: 11915743
[TBL] [Abstract][Full Text] [Related]
16. Concepts in radiotherapy and immunotherapy: anti-CD20 mechanisms of action and targets.
Maloney DG
Semin Oncol; 2005 Feb; 32(1 Suppl 1):S19-26. PubMed ID: 15786022
[TBL] [Abstract][Full Text] [Related]
17. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates.
Law CL; Cerveny CG; Gordon KA; Klussman K; Mixan BJ; Chace DF; Meyer DL; Doronina SO; Siegall CB; Francisco JA; Senter PD; Wahl AF
Clin Cancer Res; 2004 Dec; 10(23):7842-51. PubMed ID: 15585616
[TBL] [Abstract][Full Text] [Related]
18. Correspondence re: T. Davis et al., therapy of B-cell lymphoma with anti-CD20 antibodies can result in loss of CD20 antigen expression. Clin. Cancer Res., 5: 611-615, 1999.
Grillo-López AJ; Kunkel L
Clin Cancer Res; 2000 Jan; 6(1):317-8. PubMed ID: 10656464
[No Abstract] [Full Text] [Related]
19. [Relapse of diffuse large B cell lymphoma to CD20-negative multiple cutaneous tumors immediately after anti-CD20 monoclonal antibody (rituximab) therapy].
Iguchi T; Miyazawa K; Okabe S; Kawakubo K; Shimamoto T; Kuriyama Y; Ito Y; Kimura Y; Ohyashiki K; Serizawa H; Iwaya K; Mukai K
Rinsho Ketsueki; 2004 Oct; 45(10):1129-34. PubMed ID: 15553050
[TBL] [Abstract][Full Text] [Related]
20. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
Jazirehi AR; Bonavida B
Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]